{"id":588182,"date":"2026-09-11T00:00:00","date_gmt":"2026-09-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-landscape-forecast-disease-landscape-forecast-2\/"},"modified":"2026-09-12T23:01:06","modified_gmt":"2026-09-12T23:01:06","slug":"dlsfon0010-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (Major Markets)"},"content":{"rendered":"<p>Squamous cell carcinoma of the head and neck (<abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and neck. Chemotherapy remains standard in locally advanced <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, but the recent approval of perioperative pembrolizumab is expected to reshape early-stage management. Targeted therapies are frequently prescribed to patients with metastatic disease. The usual treatment algorithm starts with a <abbr data-abbreviation-entity=\"5174\" title=\"programmed cell death-1\">PD-1<\/abbr>-targeting antibody (pembrolizumab [Keytruda \/ Keytruda Qlex]) for metastatic disease, followed by an <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr>-targeting agent (cetuximab [Erbitux]) after progression. The expected approval of petosemtamab (in combination with pembrolizumab) will significantly impact treatment in the metastatic settings during the 2025-2035 forecast period. Ficlatuzumab (in combination with cetuximab), <abbr data-abbreviation-entity=\"4958\" title=\"subcutaneous\">SC<\/abbr> amivantamab (Rybrevant Faspro) and petosemtamab in later-line treatment are expected to further reshape the treatment landscape for patients with metastatic disease. The approval of toripalimab (Loqtorzi) is setting a new treatment paradigm for nasopharyngeal carcinoma (<abbr data-abbreviation-entity=\"10822\" title=\"nasopharyngeal carcinoma\">NPC<\/abbr>)<abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">,<\/abbr> with strong adoption anticipated. The recently approved penpulimab and tislelizumab (Tevimbra) are expected to see more limited uptake among these patients.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the sizes of the clinically and commercially relevant drug-treatable populations in this market, and how will drug-treatment rates change over time?<\/li>\n<li>What barriers and drivers will influence the adoption of <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> therapies during the forecast period?<\/li>\n<li>How will the entry of new pembrolizumab-based combinations, such as petosemtamab, impact the treatment for metastatic, first-line <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?<\/li>\n<li>What are the key market drivers and constraints, and how is the market expected to evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-588182","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/588182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=588182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}